Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC

Cue Biopharma, Inc.

2024-Q3 EPS reported -$0.62 revenue$7,711,000

Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.
Cash $32.4M, expected to fund operations into Q4 2025; $12M public offering priced in quarter.
CUE-101 + KEYTRUDA Phase 1 data: 46% ORR, 91.3% 12-month OS, 21.8-month mOS in 1L HPV+ HNSCC.
CUE-102 monotherapy: 67% DCR in late-stage pancreatic cancer; favorable tolerability with no DLTs.
Appointed Lucinda Warren as Chief Business Officer; preclinical autoimmune programs advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.